Dianthus Therapeutics Inc. (DNTH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.04B
Last updated: Nov 17, 2026 at 4:15 PM ET
Dianthus Therapeutics Inc. (DNTH) Statistics
Dianthus Therapeutics (DNTH) has a market cap of $5.04B and an enterprise value of $4.99B. It kept -7107.03% of revenue as net income over the last 12 months. Its share count is up 51.72% from a year earlier.
Total Valuation
Enterprise value is 1.10% below the market cap, as cash exceeds debt.
| Market Cap | $5.04B |
|---|---|
| Enterprise Value | $4.99B |
| Latest price (Nov 17, 2026) | $86.98 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 112.93% over 52 weeks and trades 0.75% below its 50-day average.
| Beta (1Y) | 0.99 |
|---|---|
| 52-Week Change | +112.93% |
| 1-Month Change | +16.69% |
| 3-Month Change | -23.50% |
| 6-Month Change | +1.53% |
| Total Return (1Y) | +112.93% |
| Total Return (3Y CAGR) | +97.12% |
| Return vs SPY (1Y) | +101.52% |
| Max Drawdown (1Y) | -37.83% |
| Max Drawdown (3Y) | -53.48% |
| Sharpe Ratio (1Y) | 1.34 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $87.64 |
| 200-Day Average | $87.27 |
| 52-Week Range | $35.84 to $117.88 |
| RSI (14 Days) | 51.6 |
| Average Volume (20 Days) | 838.54K |
Financial Position
Current assets cover 30.02x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 30.02x |
|---|---|
| Quick Ratio | 30.02x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -16.28% and return on assets is -15.84% over the last 12 months.
| Return on Equity (ROE) | -16.28% |
|---|---|
| Return on Assets (ROA) | -15.84% |
| ROA (5Y Average) | -29.86% |
| ROIC (5Y Average) | -28.65% |
| Asset Turnover | 0.00x |
| Receivables Turnover | 8.27x |
Scores
DNTH has an Altman Z-Score of 85.58, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 85.58 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $2.84M over the last 12 months is up 14.26% from the 12 months before.
| Revenue | $2.84M |
|---|---|
| Revenue Growth (YoY) | +14.26% |
| Gross Profit | $2.84M |
| Operating Income | -$236.03M |
| Pretax Income | -$202.10M |
| Net Income | -$202.12M |
| Reported EPS (TTM) | -$3.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 96.88% of the $1.28B in total assets.
| Cash and Equivalents | $55.69M |
|---|---|
| Total Debt | $0 |
| Net Cash | $55.69M |
| Net Cash Per Share | $0.97 |
| Working Capital | $827.52M |
| Shareholder Equity | $1.24B |
| Book Value Per Share | $21.65 |
| Total Assets | $1.28B |
| Total Liabilities | $34.82M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $697.00K of capital spending, operating cash flow left -$175.85M of free cash flow.
| Operating Cash Flow | -$175.15M |
|---|---|
| Capital Expenditures | $697.00K |
| Free Cash Flow | -$175.85M |
| FCF Per Share | -$3.14 |
| Depreciation and Amortization | $8.48M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -8299.16%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -8299.16% |
| Pretax Margin | -7106.29% |
| Net Margin | -7107.03% |
| FCF Margin | -6183.23% |
Growth
Revenue fell 31.80% a year over 3 years.
| Revenue Growth (3Y CAGR) | -31.80% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -40.82% |
| Tangible Book Per Share Growth (2Y CAGR) | -40.82% |
Dividends and Yields
DNTH does not pay a dividend. Its free cash flow yield is -3.53%.
| FCF Yield | -3.53% |
|---|---|
| Buyback Yield | -3.15% |
| Shareholder Yield | -3.15% |
Stock Splits
The last split was a 1-for-16 reverse split on Sep 12, 2023.
| Last Split Date | Sep 12, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:16 |
Analyst Forecast
Consensus estimates put revenue growth at -0.50% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -0.50% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DNTH
What is DNTH's market cap?
Dianthus Therapeutics has a market cap of $5.04B. Its enterprise value, which adds debt and subtracts cash, is $4.99B.
How many shares of DNTH are outstanding?
Dianthus Therapeutics has 57.34M shares outstanding. The count is up 51.72% from a year earlier.
Does DNTH pay a dividend?
No. Dianthus Therapeutics does not pay a dividend.
How much debt does DNTH have?
Dianthus Therapeutics has $0 of total debt and $55.69M of cash and equivalents, a net cash position of $55.69M.
DNTH pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors